Maintenance Therapy in the Primary Treatment of Epithelial Ovarian Cancer

被引:0
|
作者
Ayoub, Hadeal [1 ]
McDonald, Megan E. [2 ]
机构
[1] Univ Iowa, Carver Coll Med, Iowa City, IA USA
[2] Univ Iowa, Dept Obstet & Gynecol, Div Gynecol Oncol, Iowa City, IA 52242 USA
来源
CLINICAL OBSTETRICS AND GYNECOLOGY | 2020年 / 63卷 / 01期
关键词
ovarian cancer; maintenance therapy; consolidation therapy; RANDOMIZED-TRIAL; ONCOLOGY-GROUP; DOUBLE-BLIND; PHASE-II; BEVACIZUMAB; PLATINUM; CHEMOTHERAPY; PACLITAXEL; CARCINOMA;
D O I
10.1097/GRF.0000000000000514
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Despite aggressive upfront treatment with a combination of surgery and chemotherapy, most women with advanced epithelial malignancy will experience disease recurrence. The goal of treatment in the recurrent setting shifts away from a curative approach towards palliation of symptoms. In an attempt to delay time to first recurrence, the concept of maintenance chemotherapy emerged. This paper reviews the available literature evaluating the use of maintenance chemotherapy in the primary treatment setting and its effect on progression-free survival and overall survival.
引用
收藏
页码:80 / 85
页数:6
相关论文
共 50 条
  • [31] Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
    Sudeep Gupta
    Shona Nag
    Shyam Aggarwal
    Amit Rauthan
    Narayanankutty Warrier
    Journal of Ovarian Research, 12
  • [33] Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives
    Salutari, Vanda
    Giudice, Elena
    Lorusso, Domenica
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2024, 36 (01) : 9 - 17
  • [34] Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review
    Gupta, Sudeep
    Nag, Shona
    Aggarwal, Shyam
    Rauthan, Amit
    Warrier, Narayanankutty
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (01)
  • [35] Patient preferences for maintenance PARP therapy in ovarian cancer treatment.
    Havrilesky, Laura Jean
    Lim, Stephanie
    Yang, Jui-Chen
    Lorenzo, Amelia
    Ehrisman, Jessie A.
    Secord, Angeles Alvarez
    Johnson, Reed
    Reed, Shelby D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment
    Havrilesky, Laura J.
    Lim, Stephanie
    Ehrisman, Jessie A.
    Lorenzo, Amelia
    Secord, Angeles Alvarez
    Yang, Jui-Chen
    Johnson, F. Reed
    Gonzalez, Juan Marcos
    Reed, Shelby D.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (03) : 561 - 567
  • [37] Endocrine therapy in epithelial ovarian cancer
    Langdon, Simon P.
    Gourley, Charlie
    Gabra, Hani
    Stanley, Barbara
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (02) : 109 - 117
  • [38] Hormonal therapy in epithelial ovarian cancer
    Rao, Gautam G.
    Miller, David Scott
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (01) : 43 - 47
  • [39] Hormonal therapy for epithelial ovarian cancer
    Markman, Maurie
    WOMENS HEALTH, 2006, 2 (06) : 847 - 851
  • [40] Hormone therapy in epithelial ovarian cancer
    Makar, AP
    ENDOCRINE-RELATED CANCER, 2000, 7 (02) : 85 - 93